A Phase 2 interventional study of Filgotinib in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 111 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 5th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
University Hospital, Toulouse · Sites in France
Ages 18–65
Universita di Verona · Sites in Italy
Ages 18–65
R.Bos · Sites in Netherlands
Ages 18–101
Leiden University Medical Center · Sites in Netherlands
Ages 18+
By country, each count listing its studies:
GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 739 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 287 across the 17 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 8 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Study GLPG0634-CL-203 (NCT01888874) were rolled-over to receive an oral dose of filgotinib at a daily dose of 200 milligrams (mg) in this extension study, with the exception of male participants in the United States (US) who were limited to a daily dose of 100 mg due to a Food and Drug Administration (FDA) requirement based on a non-clinical finding. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. In case of intolerance or for safety reasons, and as per investigator's discretion, a daily dose of filgotinib 200 mg could be decreased to 100 mg per day, and later returned to 200 mg per day after the reasons for decreasing the dose were resolved.
Drug: Filgotinib
Participants from Study GLPG0634-CL-204 (NCT01894516) were rolled-over to receive oral dose of filgotinib tablet at 200 mg once daily (q.d) in this extension study. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. Participants started the study with the same dose level (filgotinib 200 mg per day) and in case of intolerance or safety reasons and as per investigator's discretion, the daily dose of filgotinib was decreased to 100 mg q.d and was returned to 200 mg per day after the reasons for decreasing the dose had resolved and at the investigator's discretion.
Drug: Filgotinib
Administered as Oral Tablets
Also known as: GS-6034, GLPG0634
Number of Participants Experiencing Treatment-Emergent Adverse Events
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.
Time frame: From First dose to Week 437
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)
The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR20 Response: Observed Case (OC)
The ACR response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR50 Response: NRI
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR50 Response: OC
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR70 Response: NRI
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR70 Response: OC
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
ACR N% Improvement (ACR-N) Response: OC
ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS \[taken from the HAQ-DI\], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC
The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP using the formula: DAS28(CRP) = 0.56 \* Square root \[SQRT\] (TJC28) + 0.28 \* SQRT(SJC28) + 0.36 \* Ln(CRP+1) + 0.014 \* SGA + 0.96 and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.
Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Simple Disease Activity Index (SDAI): OC
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.
Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Clinical Disease Activity Index (CDAI): OC
The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.
Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC
DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None= Actual DAS28(CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28(CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28(CRP) from baseline \> 1.2, or Actual DAS28(CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2; Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 1.2.
Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR/EULAR Remission: NRI
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Percentage of Participants Achieving ACR/EULAR Remission: OC
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Change From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.
Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Change From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.
Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Change From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC
FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.
Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Participants with moderately to severely active rheumatoid arthritis were enrolled in this study.
| Milestone | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Started | 497 | 242 |
| Male us participants | 7 | 0 |
| Completed | 161 | 81 |
| Not completed | 336 | 161 |
| Withdrew: Adverse event | 165 | 101 |
| Withdrew: Withdrawal by subject | 90 | 29 |
| Withdrew: Lost to follow-up | 12 | 9 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Sponsor request | 38 | 15 |
| Withdrew: Treatment failure | 3 | 2 |
| Withdrew: Use of non-permitted concurrent therapy | 3 | 0 |
| Withdrew: Adverse event and treatment failure | 0 | 2 |
| Withdrew: Non-compliance with study procedures | 2 | 0 |
| Withdrew: Not defined | 21 | 3 |
An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.
| participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Number of Participants Experiencing Treatment-Emergent Adverse Events | 453 | 223 |
The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 76.5 | 77.3 |
| Week 12 | 83.9 | 83.1 |
| Week 24 | 75.3 | 77.7 |
| Week 36 | 75.1 | 75.2 |
| Week 48 | 71.8 | 71.1 |
| Week 60 | 67.8 | 69.4 |
| Week 72 | 68.4 | 62.4 |
| Week 84 | 65.8 | 64.5 |
| Week 96 | 68.2 | 61.6 |
| Week 108 | 61.6 | 58.3 |
| Week 120 | 57.7 | 59.1 |
| Week 132 | 59.0 | 57.4 |
| Week 144 | 56.3 | 57.4 |
| Week 156 | 50.7 | 50.4 |
| Week 168 | 52.3 | 47.9 |
| Week 180 | 52.1 | 51.7 |
| Week 192 | 49.7 | 48.8 |
| Week 204 | 48.9 | 50.8 |
| Week 216 | 45.7 | 50.8 |
| Week 228 | 47.9 | 48.3 |
| Week 240 | 45.5 | 43.8 |
| Week 252 | 42.1 | 42.1 |
| Week 264 | 39.4 | 40.9 |
| Week 276 | 39.6 | 44.2 |
| Week 288 | 36.6 | 38.8 |
| Week 300 | 35.6 | 39.7 |
| Week 312 | 36.8 | 36.0 |
| Week 324 | 36.6 | 37.2 |
| Week 336 | 34.6 | 35.5 |
| Week 348 | 33.2 | 34.7 |
| Week 360 | 31.4 | 31.4 |
| Week 372 | 30.0 | 28.9 |
| Week 384 | 28.0 | 27.7 |
| Week 396 | 26.2 | 28.5 |
| Week 408 | 0.4 | 0.4 |
The ACR response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 77.4 | 79.6 |
| Week 12 | 86.2 | 87.4 |
| Week 24 | 84.8 | 89.5 |
| Week 36 | 86.5 | 89.2 |
| Week 48 | 84.6 | 86.9 |
| Week 60 | 84.5 | 90.8 |
| Week 72 | 87.9 | 87.8 |
| Week 84 | 87.2 | 91.8 |
| Week 96 | 89.9 | 91.4 |
| Week 108 | 86.0 | 89.2 |
| Week 120 | 85.9 | 91.1 |
| Week 132 | 88.0 | 92.1 |
| Week 144 | 86.7 | 89.7 |
| Week 156 | 87.2 | 89.7 |
| Week 168 | 87.2 | 84.1 |
| Week 180 | 89.0 | 88.7 |
| Week 192 | 87.9 | 88.7 |
| Week 204 | 89.3 | 91.8 |
| Week 216 | 86.6 | 93.2 |
| Week 228 | 89.5 | 92.9 |
| Week 240 | 88.3 | 89.1 |
| Week 252 | 89.7 | 91.9 |
| Week 264 | 86.3 | 90.8 |
| Week 276 | 91.6 | 93.9 |
| Week 288 | 87.9 | 85.5 |
| Week 300 | 88.1 | 91.4 |
| Week 312 | 88.8 | 87.0 |
| Week 324 | 89.7 | 86.5 |
| Week 336 | 88.7 | 88.7 |
| Week 348 | 87.8 | 91.3 |
| Week 360 | 86.7 | 88.4 |
| Week 372 | 89.8 | 85.4 |
| Week 384 | 85.3 | 84.8 |
| Week 396 | 85.0 | 92.0 |
| Week 408 | 66.7 | 50.0 |
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 48.5 | 45.0 |
| Week 12 | 60.8 | 61.2 |
| Week 24 | 56.7 | 60.3 |
| Week 36 | 58.1 | 60.3 |
| Week 48 | 55.9 | 53.7 |
| Week 60 | 53.9 | 51.2 |
| Week 72 | 53.3 | 47.1 |
| Week 84 | 52.9 | 51.7 |
| Week 96 | 55.5 | 47.1 |
| Week 108 | 49.1 | 43.8 |
| Week 120 | 48.7 | 43.8 |
| Week 132 | 47.5 | 42.1 |
| Week 144 | 46.9 | 43.0 |
| Week 156 | 42.3 | 35.1 |
| Week 168 | 43.9 | 34.7 |
| Week 180 | 42.7 | 38.8 |
| Week 192 | 38.4 | 37.6 |
| Week 204 | 37.8 | 38.4 |
| Week 216 | 36.0 | 35.1 |
| Week 228 | 38.4 | 34.7 |
| Week 240 | 34.2 | 33.9 |
| Week 252 | 32.0 | 32.6 |
| Week 264 | 30.6 | 33.1 |
| Week 276 | 29.6 | 36.0 |
| Week 288 | 29.8 | 33.5 |
| Week 300 | 29.2 | 28.9 |
| Week 312 | 29.0 | 26.9 |
| Week 324 | 30.0 | 28.1 |
| Week 336 | 27.4 | 25.6 |
| Week 348 | 27.2 | 26.4 |
| Week 360 | 24.5 | 24.0 |
| Week 372 | 23.7 | 24.4 |
| Week 384 | 21.3 | 21.5 |
| Week 396 | 19.9 | 20.7 |
| Week 408 | 0.4 | 0.4 |
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 49.4 | 46.4 |
| Week 12 | 62.4 | 64.1 |
| Week 24 | 64.1 | 69.2 |
| Week 36 | 67.2 | 71.6 |
| Week 48 | 65.9 | 65.3 |
| Week 60 | 67.3 | 66.3 |
| Week 72 | 68.5 | 65.9 |
| Week 84 | 69.9 | 73.5 |
| Week 96 | 73.2 | 69.5 |
| Week 108 | 68.3 | 66.7 |
| Week 120 | 72.9 | 67.5 |
| Week 132 | 71.3 | 66.7 |
| Week 144 | 71.3 | 67.5 |
| Week 156 | 72.4 | 63.0 |
| Week 168 | 73.4 | 60.9 |
| Week 180 | 72.6 | 67.1 |
| Week 192 | 67.5 | 67.9 |
| Week 204 | 69.6 | 69.4 |
| Week 216 | 68.1 | 64.4 |
| Week 228 | 72.1 | 66.7 |
| Week 240 | 66.9 | 69.5 |
| Week 252 | 68.5 | 71.2 |
| Week 264 | 66.7 | 74.8 |
| Week 276 | 68.1 | 76.3 |
| Week 288 | 70.8 | 73.6 |
| Week 300 | 72.5 | 66.7 |
| Week 312 | 69.6 | 64.4 |
| Week 324 | 72.7 | 65.4 |
| Week 336 | 70.1 | 63.9 |
| Week 348 | 71.8 | 69.6 |
| Week 360 | 67.8 | 67.4 |
| Week 372 | 70.7 | 71.1 |
| Week 384 | 64.2 | 65.0 |
| Week 396 | 65.6 | 64.9 |
| Week 408 | 66.7 | 50.0 |
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 30.0 | 23.1 |
| Week 12 | 36.8 | 36.4 |
| Week 24 | 37.8 | 39.3 |
| Week 36 | 40.6 | 37.2 |
| Week 48 | 39.4 | 36.4 |
| Week 60 | 36.4 | 34.3 |
| Week 72 | 38.0 | 30.2 |
| Week 84 | 36.8 | 34.3 |
| Week 96 | 39.6 | 28.1 |
| Week 108 | 35.4 | 29.8 |
| Week 120 | 36.0 | 31.0 |
| Week 132 | 32.8 | 29.3 |
| Week 144 | 31.6 | 28.5 |
| Week 156 | 26.8 | 22.3 |
| Week 168 | 30.8 | 24.0 |
| Week 180 | 30.8 | 25.6 |
| Week 192 | 26.6 | 25.2 |
| Week 204 | 26.6 | 24.8 |
| Week 216 | 26.4 | 23.1 |
| Week 228 | 27.2 | 24.4 |
| Week 240 | 21.5 | 21.5 |
| Week 252 | 21.7 | 20.7 |
| Week 264 | 23.1 | 22.7 |
| Week 276 | 21.3 | 24.8 |
| Week 288 | 22.1 | 24.8 |
| Week 300 | 22.5 | 19.8 |
| Week 312 | 23.1 | 19.8 |
| Week 324 | 21.5 | 21.1 |
| Week 336 | 20.3 | 17.8 |
| Week 348 | 19.7 | 19.0 |
| Week 360 | 17.7 | 16.1 |
| Week 372 | 16.7 | 17.4 |
| Week 384 | 14.9 | 14.9 |
| Week 396 | 14.9 | 14.5 |
| Week 408 | 0.4 | 0.4 |
The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 30.3 | 23.5 |
| Week 12 | 37.7 | 38.1 |
| Week 24 | 42.7 | 45.0 |
| Week 36 | 46.9 | 44.6 |
| Week 48 | 46.6 | 44.0 |
| Week 60 | 45.5 | 44.6 |
| Week 72 | 48.7 | 42.2 |
| Week 84 | 48.9 | 48.5 |
| Week 96 | 52.5 | 41.2 |
| Week 108 | 49.7 | 45.3 |
| Week 120 | 53.8 | 47.5 |
| Week 132 | 48.9 | 46.4 |
| Week 144 | 48.3 | 44.2 |
| Week 156 | 45.5 | 40.0 |
| Week 168 | 51.5 | 42.6 |
| Week 180 | 52.4 | 44.0 |
| Week 192 | 46.6 | 45.2 |
| Week 204 | 49.1 | 45.1 |
| Week 216 | 49.4 | 42.4 |
| Week 228 | 50.9 | 46.8 |
| Week 240 | 42.1 | 43.3 |
| Week 252 | 46.4 | 45.5 |
| Week 264 | 50.7 | 51.4 |
| Week 276 | 48.8 | 53.1 |
| Week 288 | 52.4 | 54.5 |
| Week 300 | 55.4 | 45.7 |
| Week 312 | 55.3 | 47.5 |
| Week 324 | 52.2 | 49.0 |
| Week 336 | 51.8 | 44.3 |
| Week 348 | 51.6 | 50.0 |
| Week 360 | 49.2 | 44.8 |
| Week 372 | 49.1 | 50.0 |
| Week 384 | 45.4 | 45.0 |
| Week 396 | 49.0 | 45.5 |
| Week 408 | 66.7 | 50.0 |
ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS \[taken from the HAQ-DI\], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.
| percentage of improvement | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 48.1 ± 30.29 | 46.3 ± 27.77 |
| Week 12 | 56.3 ± 28.43 | 56.3 ± 27.13 |
| Week 24 | 57.9 ± 29.64 | 60.8 ± 27.76 |
| Week 36 | 59.8 ± 29.70 | 60.7 ± 27.95 |
| Week 48 | 59.6 ± 30.69 | 58.9 ± 28.65 |
| Week 60 | 59.9 ± 29.97 | 60.1 ± 28.43 |
| Week 72 | 61.4 ± 28.92 | 59.0 ± 28.47 |
| Week 84 | 61.6 ± 29.07 | 63.6 ± 26.74 |
| Week 96 | 64.8 ± 28.61 | 61.2 ± 26.87 |
| Week 108 | 61.2 ± 30.22 | 60.9 ± 28.69 |
| Week 120 | 63.4 ± 29.25 | 61.1 ± 28.72 |
| Week 132 | 62.3 ± 29.15 | 61.3 ± 28.52 |
| Week 144 | 61.7 ± 28.99 | 60.8 ± 29.12 |
| Week 156 | 61.5 ± 28.05 | 58.0 ± 27.70 |
| Week 168 | 62.8 ± 29.75 | 56.9 ± 30.25 |
| Week 180 | 63.2 ± 28.29 | 59.9 ± 29.79 |
| Week 192 | 60.4 ± 29.15 | 61.5 ± 27.30 |
| Week 204 | 62.3 ± 28.64 | 61.9 ± 26.79 |
| Week 216 | 61.6 ± 29.87 | 61.4 ± 26.86 |
| Week 228 | 64.2 ± 27.83 | 63.0 ± 26.45 |
| Week 240 | 59.8 ± 28.22 | 60.6 ± 28.48 |
| Week 252 | 62.4 ± 28.71 | 62.5 ± 26.24 |
| Week 264 | 63.4 ± 29.81 | 64.4 ± 27.05 |
| Week 276 | 63.3 ± 28.27 | 65.9 ± 25.42 |
| Week 288 | 65.1 ± 29.68 | 63.0 ± 29.82 |
| Week 300 | 64.9 ± 30.16 | 61.9 ± 27.14 |
| Week 312 | 64.8 ± 29.89 | 59.9 ± 30.37 |
| Week 324 | 65.9 ± 27.39 | 61.2 ± 30.98 |
| Week 336 | 62.7 ± 29.35 | 59.8 ± 28.90 |
| Week 348 | 64.8 ± 29.26 | 62.8 ± 28.29 |
| Week 360 | 62.7 ± 29.81 | 61.2 ± 28.32 |
| Week 372 | 64.2 ± 28.58 | 64.6 ± 29.43 |
| Week 384 | 60.0 ± 30.27 | 62.9 ± 30.43 |
| Week 396 | 61.5 ± 31.34 | 64.7 ± 28.98 |
| Week 408 | 65.9 ± 41.08 | 35.4 ± 50.04 |
The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP using the formula: DAS28(CRP) = 0.56 \* Square root \[SQRT\] (TJC28) + 0.28 \* SQRT(SJC28) + 0.36 \* Ln(CRP+1) + 0.014 \* SGA + 0.96 and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | -2.7 ± 1.40 | -2.6 ± 1.28 |
| Change from Core Baseline at Week 12 | -3.1 ± 1.28 | -3.1 ± 1.22 |
| Change from Core Baseline at Week 24 | -3.2 ± 1.29 | -3.2 ± 1.33 |
| Change from Core Baseline at Week 36 | -3.3 ± 1.28 | -3.3 ± 1.22 |
| Change from Core Baseline at Week 48 | -3.3 ± 1.32 | -3.3 ± 1.26 |
| Change from Core Baseline at Week 60 | -3.3 ± 1.22 | -3.4 ± 1.17 |
| Change from Core Baseline at Week 72 | -3.3 ± 1.23 | -3.4 ± 1.21 |
| Change from Core Baseline at Week 84 | -3.4 ± 1.21 | -3.5 ± 1.09 |
| Change from Core Baseline at Week 96 | -3.4 ± 1.22 | -3.4 ± 1.13 |
| Change from Core Baseline at Week 108 | -3.4 ± 1.22 | -3.3 ± 1.21 |
| Change from Core Baseline at Week 120 | -3.4 ± 1.20 | -3.5 ± 1.14 |
| Change from Core Baseline at Week 132 | -3.3 ± 1.21 | -3.5 ± 1.26 |
| Change from Core Baseline at Week 144 | -3.4 ± 1.19 | -3.4 ± 1.15 |
| Change from Core Baseline at Week 156 | -3.4 ± 1.22 | -3.4 ± 1.28 |
| Change from Core Baseline at Week 168 | -3.4 ± 1.27 | -3.4 ± 1.20 |
| Change from Core Baseline at Week 180 | -3.4 ± 1.12 | -3.4 ± 1.21 |
| Change from Core Baseline at Week 192 | -3.3 ± 1.16 | -3.5 ± 1.13 |
| Change from Core Baseline at Week 204 | -3.4 ± 1.16 | -3.5 ± 1.06 |
| Change from Core Baseline at Week 216 | -3.4 ± 1.16 | -3.5 ± 1.15 |
| Change from Core Baseline at Week 228 | -3.5 ± 1.12 | -3.5 ± 1.09 |
| Change from Core Baseline at Week 240 | -3.4 ± 1.13 | -3.4 ± 1.19 |
| Change from Core Baseline at Week 252 | -3.5 ± 1.11 | -3.6 ± 1.24 |
| Change from Core Baseline at Week 264 | -3.5 ± 1.19 | -3.6 ± 1.20 |
| Change from Core Baseline at Week 276 | -3.5 ± 1.10 | -3.6 ± 1.17 |
| Change from Core Baseline at Week 288 | -3.5 ± 1.22 | -3.6 ± 1.28 |
| Change from Core Baseline at Week 300 | -3.6 ± 1.19 | -3.5 ± 1.23 |
| Change from Core Baseline at Week 312 | -3.5 ± 1.27 | -3.4 ± 1.30 |
| Change from Core Baseline at Week 324 | -3.6 ± 1.14 | -3.5 ± 1.24 |
| Change from Core Baseline at Week 336 | -3.5 ± 1.17 | -3.4 ± 1.16 |
| Change from Core Baseline at Week 348 | -3.5 ± 1.20 | -3.6 ± 1.14 |
| Change from Core Baseline at Week 360 | -3.6 ± 1.21 | -3.4 ± 1.13 |
| Change from Core Baseline at Week 372 | -3.6 ± 1.18 | -3.6 ± 1.26 |
| Change from Core Baseline at Week 384 | -3.4 ± 1.24 | -3.5 ± 1.26 |
| Change from Core Baseline at Week 396 | -3.5 ± 1.38 | -3.8 ± 1.12 |
| Change from Core Baseline at Week 408 | -3.8 ± 0.97 | -2.8 ± 0.25 |
SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | -30.2 ± 15.49 | -29.8 ± 14.27 |
| Change from Core Baseline at Week 12 | -33.4 ± 14.16 | -34.1 ± 13.79 |
| Change from Core Baseline at Week 24 | -34.0 ± 14.19 | -35.0 ± 14.65 |
| Change from Core Baseline at Week 36 | -34.7 ± 13.98 | -35.9 ± 13.42 |
| Change from Core Baseline at Week 48 | -34.7 ± 14.38 | -36.2 ± 14.08 |
| Change from Core Baseline at Week 60 | -35.3 ± 13.57 | -36.3 ± 12.85 |
| Change from Core Baseline at Week 72 | -35.4 ± 13.38 | -36.7 ± 13.41 |
| Change from Core Baseline at Week 84 | -35.6 ± 13.38 | -37.3 ± 13.12 |
| Change from Core Baseline at Week 96 | -36.2 ± 13.31 | -36.8 ± 13.47 |
| Change from Core Baseline at Week 108 | -36.0 ± 13.56 | -36.6 ± 13.65 |
| Change from Core Baseline at Week 120 | -36.1 ± 13.28 | -37.4 ± 12.90 |
| Change from Core Baseline at Week 132 | -35.6 ± 13.38 | -36.9 ± 14.25 |
| Change from Core Baseline at Week 144 | -35.7 ± 13.15 | -36.9 ± 13.12 |
| Change from Core Baseline at Week 156 | -35.5 ± 13.36 | -36.9 ± 14.46 |
| Change from Core Baseline at Week 168 | -35.8 ± 14.18 | -36.9 ± 13.84 |
| Change from Core Baseline at Week 180 | -36.2 ± 12.72 | -36.9 ± 13.33 |
| Change from Core Baseline at Week 192 | -35.5 ± 12.74 | -38.2 ± 13.66 |
| Change from Core Baseline at Week 204 | -35.8 ± 12.78 | -38.5 ± 13.72 |
| Change from Core Baseline at Week 216 | -36.1 ± 12.92 | -38.0 ± 13.85 |
| Change from Core Baseline at Week 228 | -36.8 ± 12.38 | -37.9 ± 12.87 |
| Change from Core Baseline at Week 240 | -35.9 ± 12.69 | -37.1 ± 14.38 |
| Change from Core Baseline at Week 252 | -37.2 ± 12.63 | -38.6 ± 14.85 |
| Change from Core Baseline at Week 264 | -37.3 ± 12.98 | -39.2 ± 14.59 |
| Change from Core Baseline at Week 276 | -37.5 ± 12.18 | -38.6 ± 13.98 |
| Change from Core Baseline at Week 288 | -37.0 ± 13.22 | -38.6 ± 15.09 |
| Change from Core Baseline at Week 300 | -37.5 ± 13.55 | -38.0 ± 15.38 |
| Change from Core Baseline at Week 312 | -37.1 ± 13.71 | -37.7 ± 15.54 |
| Change from Core Baseline at Week 324 | -37.7 ± 13.06 | -38.1 ± 15.56 |
| Change from Core Baseline at Week 336 | -36.7 ± 12.52 | -36.6 ± 14.36 |
| Change from Core Baseline at Week 348 | -37.0 ± 12.53 | -37.2 ± 13.02 |
| Change from Core Baseline at Week 360 | -37.4 ± 12.83 | -36.3 ± 13.05 |
| Change from Core Baseline at Week 372 | -37.3 ± 12.68 | -37.8 ± 13.64 |
| Change from Core Baseline at Week 384 | -36.5 ± 12.64 | -36.5 ± 14.58 |
| Change from Core Baseline at Week 396 | -36.3 ± 14.32 | -39.5 ± 13.50 |
| Change from Core Baseline at Week 408 | -40.4 ± 12.91 | -35.6 ± 5.98 |
The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | -28.8 ± 14.58 | -28.0 ± 13.68 |
| Change from Core Baseline at Week 12 | -31.8 ± 13.45 | -32.4 ± 12.76 |
| Change from Core Baseline at Week 24 | -32.4 ± 13.63 | -32.9 ± 13.79 |
| Change from Core Baseline at Week 36 | -33.0 ± 13.44 | -33.8 ± 12.51 |
| Change from Core Baseline at Week 48 | -33.1 ± 13.79 | -34.1 ± 13.18 |
| Change from Core Baseline at Week 60 | -33.7 ± 12.97 | -34.2 ± 12.22 |
| Change from Core Baseline at Week 72 | -33.8 ± 12.73 | -34.4 ± 12.57 |
| Change from Core Baseline at Week 84 | -33.9 ± 12.82 | -35.2 ± 12.31 |
| Change from Core Baseline at Week 96 | -34.6 ± 12.76 | -34.7 ± 12.56 |
| Change from Core Baseline at Week 108 | -34.3 ± 12.96 | -34.5 ± 12.92 |
| Change from Core Baseline at Week 120 | -34.5 ± 12.70 | -35.2 ± 11.87 |
| Change from Core Baseline at Week 132 | -34.1 ± 12.82 | -34.7 ± 13.07 |
| Change from Core Baseline at Week 144 | -34.1 ± 12.63 | -34.9 ± 12.12 |
| Change from Core Baseline at Week 156 | -34.0 ± 12.74 | -34.8 ± 13.29 |
| Change from Core Baseline at Week 168 | -34.1 ± 13.64 | -34.8 ± 12.55 |
| Change from Core Baseline at Week 180 | -34.5 ± 12.10 | -34.8 ± 12.39 |
| Change from Core Baseline at Week 192 | -33.9 ± 12.10 | -35.9 ± 12.65 |
| Change from Core Baseline at Week 204 | -34.2 ± 12.26 | -36.3 ± 12.79 |
| Change from Core Baseline at Week 216 | -34.5 ± 12.18 | -36.0 ± 13.00 |
| Change from Core Baseline at Week 228 | -35.2 ± 11.69 | -35.8 ± 11.98 |
| Change from Core Baseline at Week 240 | -34.3 ± 11.99 | -35.2 ± 13.27 |
| Change from Core Baseline at Week 252 | -35.3 ± 11.94 | -36.4 ± 13.55 |
| Change from Core Baseline at Week 264 | -35.6 ± 12.15 | -36.9 ± 13.53 |
| Change from Core Baseline at Week 276 | -35.9 ± 11.38 | -36.4 ± 12.84 |
| Change from Core Baseline at Week 288 | -35.4 ± 12.28 | -36.5 ± 13.47 |
| Change from Core Baseline at Week 300 | -35.8 ± 12.84 | -35.7 ± 14.29 |
| Change from Core Baseline at Week 312 | -35.5 ± 13.10 | -35.5 ± 14.40 |
| Change from Core Baseline at Week 324 | -35.8 ± 12.30 | -36.0 ± 14.37 |
| Change from Core Baseline at Week 336 | -35.0 ± 11.76 | -34.2 ± 13.32 |
| Change from Core Baseline at Week 348 | -35.3 ± 11.70 | -34.8 ± 11.73 |
| Change from Core Baseline at Week 360 | -35.5 ± 12.00 | -34.0 ± 11.54 |
| Change from Core Baseline at Week 372 | -35.4 ± 12.46 | -33.9 ± 12.73 |
| Change from Core Baseline at Week 384 | -34.8 ± 11.82 | -32.6 ± 13.11 |
| Change from Core Baseline at Week 396 | -34.7 ± 13.28 | -34.2 ± 12.55 |
| Change from Core Baseline at Week 408 | -39.2 ± 12.87 | -34.9 ± 6.36 |
DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None= Actual DAS28(CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28(CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28(CRP) from baseline \> 1.2, or Actual DAS28(CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2; Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 1.2.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline: Good | 46.2 | 41.5 |
| Extension Baseline: Moderate | 43.6 | 48.7 |
| Extension Baseline: None | 10.2 | 9.8 |
| Week 12: Good | 59.1 | 60.3 |
| Week 12: Moderate | 35.5 | 34.9 |
| Week 12: None | 5.3 | 4.7 |
| Week 24: Good | 65.2 | 65.9 |
| Week 24: Moderate | 29.3 | 28.9 |
| Week 24: None | 5.4 | 5.2 |
| Week 36: Good | 66.4 | 66.0 |
| Week 36: Moderate | 29.7 | 30.6 |
| Week 36: None | 3.9 | 3.4 |
| Week 48: Good | 67.7 | 68.7 |
| Week 48: Moderate | 27.8 | 27.4 |
| Week 48: None | 4.5 | 4.0 |
| Week 60: Good | 67.8 | 64.2 |
| Week 60: Moderate | 29.9 | 34.2 |
| Week 60: None | 2.3 | 1.6 |
| Week 72: Good | 70.5 | 65.3 |
| Week 72: Moderate | 26.7 | 32.9 |
| Week 72: None | 2.8 | 1.7 |
| Week 84: Good | 70.3 | 69.8 |
| Week 84: Moderate | 27.6 | 29.1 |
| Week 84: None | 2.1 | 1.2 |
| Week 96: Good | 72.9 | 69.1 |
| Week 96: Moderate | 25.2 | 27.9 |
| Week 96: None | 1.9 | 3.0 |
| Week 108: Good | 74.2 | 66.7 |
| Week 108: Moderate | 23.6 | 29.6 |
| Week 108: None | 2.2 | 3.8 |
| Week 120: Good | 74.6 | 67.9 |
| Week 120: Moderate | 23.7 | 29.6 |
| Week 120: None | 1.8 | 2.5 |
| Week 132: Good | 69.1 | 69.9 |
| Week 132: Moderate | 28.8 | 27.5 |
| Week 132: None | 2.1 | 2.6 |
| Week 144: Good | 72.3 | 65.6 |
| Week 144: Moderate | 25.8 | 33.1 |
| Week 144: None | 1.8 | 1.3 |
| Week 156: Good | 69.0 | 64.7 |
| Week 156: Moderate | 28.3 | 30.9 |
| Week 156: None | 2.8 | 4.4 |
| Week 168: Good | 73.4 | 68.3 |
| Week 168: Moderate | 23.6 | 29.5 |
| Week 168: None | 3.0 | 2.2 |
| Week 180: Good | 74.0 | 68.5 |
| Week 180: Moderate | 25.3 | 28.7 |
| Week 180: None | 0.7 | 2.8 |
| Week 192: Good | 71.2 | 71.1 |
| Week 192: Moderate | 26.3 | 28.1 |
| Week 192: None | 2.5 | 0.7 |
| Week 204: Good | 73.3 | 76.3 |
| Week 204: Moderate | 23.8 | 22.2 |
| Week 204: None | 2.9 | 1.5 |
| Week 216: Good | 72.7 | 69.9 |
| Week 216: Moderate | 26.1 | 28.6 |
| Week 216: None | 1.1 | 1.5 |
| Week 228: Good | 76.4 | 70.1 |
| Week 228: Moderate | 23.6 | 29.9 |
| Week 228: None | 0 | 0 |
| Week 240: Good | 73.2 | 63.1 |
| Week 240: Moderate | 26.1 | 36.9 |
| Week 240: None | 0.8 | 0 |
| Week 252: Good | 74.2 | 73.4 |
| Week 252: Moderate | 24.5 | 25.7 |
| Week 252: None | 1.3 | 0.9 |
| Week 264: Good | 74.4 | 75.5 |
| Week 264: Moderate | 24.2 | 22.7 |
| Week 264: None | 1.3 | 1.8 |
| Week 276: Good | 74.4 | 70.2 |
| Week 276: Moderate | 25.1 | 28.1 |
| Week 276: None | 0.5 | 1.8 |
| Week 288: Good | 73.6 | 73.0 |
| Week 288: Moderate | 24.5 | 24.3 |
| Week 288: None | 1.9 | 2.7 |
| Week 300: Good | 74.8 | 74.5 |
| Week 300: Moderate | 23.8 | 25.5 |
| Week 300: None | 1.5 | 0 |
| Week 312: Good | 75.8 | 66.3 |
| Week 312: Moderate | 22.2 | 32.7 |
| Week 312: None | 1.9 | 1.0 |
| Week 324: Good | 75.7 | 71.8 |
| Week 324: Moderate | 21.8 | 26.2 |
| Week 324: None | 2.5 | 1.9 |
| Week 336: Good | 74.2 | 71.9 |
| Week 336: Moderate | 24.7 | 26.0 |
| Week 336: None | 1.0 | 2.1 |
| Week 348: Good | 76.9 | 78.5 |
| Week 348: Moderate | 21.5 | 20.4 |
| Week 348: None | 1.6 | 1.1 |
| Week 360: Good | 73.3 | 73.2 |
| Week 360: Moderate | 23.9 | 24.4 |
| Week 360: None | 2.8 | 2.4 |
| Week 372: Good | 76.8 | 77.8 |
| Week 372: Moderate | 21.3 | 18.1 |
| Week 372: None | 1.9 | 4.2 |
| Week 384: Good | 70.3 | 78.1 |
| Week 384: Moderate | 28.4 | 20.3 |
| Week 384: None | 1.3 | 1.6 |
| Week 396: Good | 73.2 | 81.0 |
| Week 396: Moderate | 21.7 | 19.0 |
| Week 396: None | 5.1 | 0 |
| Week 408: Good | 100.0 | 50.0 |
| Week 408: Moderate | 0 | 50.0 |
| Week 408: None | 0 | 0 |
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 10.1 | 7.4 |
| Week 12 | 13.1 | 11.6 |
| Week 24 | 14.9 | 15.3 |
| Week 36 | 15.3 | 14.5 |
| Week 48 | 17.7 | 14.0 |
| Week 60 | 15.5 | 12.4 |
| Week 72 | 15.5 | 12.0 |
| Week 84 | 15.1 | 12.4 |
| Week 96 | 18.3 | 11.2 |
| Week 108 | 14.9 | 10.7 |
| Week 120 | 12.3 | 13.2 |
| Week 132 | 12.1 | 12.8 |
| Week 144 | 10.5 | 9.9 |
| Week 156 | 10.9 | 8.3 |
| Week 168 | 13.9 | 7.9 |
| Week 180 | 10.3 | 11.2 |
| Week 192 | 10.1 | 10.7 |
| Week 204 | 11.1 | 9.5 |
| Week 216 | 11.5 | 7.9 |
| Week 228 | 11.9 | 9.9 |
| Week 240 | 8.9 | 7.4 |
| Week 252 | 7.8 | 7.9 |
| Week 264 | 11.3 | 7.4 |
| Week 276 | 8.9 | 9.5 |
| Week 288 | 10.1 | 9.9 |
| Week 300 | 10.9 | 8.7 |
| Week 312 | 10.5 | 7.9 |
| Week 324 | 9.5 | 10.3 |
| Week 336 | 8.5 | 7.4 |
| Week 348 | 9.1 | 9.1 |
| Week 360 | 9.3 | 6.2 |
| Week 372 | 8.2 | 6.6 |
| Week 384 | 6.6 | 4.5 |
| Week 396 | 7.8 | 5.4 |
| Week 408 | 0.4 | 0 |
A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.
| percentage of participants | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Extension Baseline | 10.1 | 7.5 |
| Week 12 | 13.3 | 11.9 |
| Week 24 | 16.6 | 17.2 |
| Week 36 | 17.5 | 17.0 |
| Week 48 | 20.7 | 16.7 |
| Week 60 | 19.2 | 15.9 |
| Week 72 | 19.7 | 16.7 |
| Week 84 | 19.7 | 17.3 |
| Week 96 | 24.0 | 16.1 |
| Week 108 | 20.6 | 16.1 |
| Week 120 | 17.9 | 20.0 |
| Week 132 | 17.9 | 19.7 |
| Week 144 | 15.8 | 15.2 |
| Week 156 | 18.2 | 14.4 |
| Week 168 | 23.1 | 13.7 |
| Week 180 | 17.4 | 18.8 |
| Week 192 | 17.4 | 18.8 |
| Week 204 | 19.9 | 17.0 |
| Week 216 | 21.2 | 14.2 |
| Week 228 | 22.0 | 18.6 |
| Week 240 | 16.8 | 14.6 |
| Week 252 | 16.3 | 16.8 |
| Week 264 | 24.2 | 16.2 |
| Week 276 | 20.2 | 20.0 |
| Week 288 | 23.3 | 21.6 |
| Week 300 | 26.3 | 19.6 |
| Week 312 | 24.8 | 18.1 |
| Week 324 | 22.7 | 23.8 |
| Week 336 | 21.3 | 18.4 |
| Week 348 | 23.7 | 23.4 |
| Week 360 | 24.9 | 16.7 |
| Week 372 | 24.6 | 18.8 |
| Week 384 | 20.0 | 12.9 |
| Week 396 | 25.2 | 16.3 |
| Week 408 | 66.7 | 0 |
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | 9.2 ± 9.11 | 9.5 ± 8.85 |
| Change from Core Baseline at Week 48 | 11.3 ± 9.45 | 11.5 ± 8.74 |
| Change from Core Baseline at Week 96 | 12.2 ± 9.70 | 11.8 ± 8.87 |
| Change from Core Baseline at Week 144 | 11.8 ± 9.86 | 12.2 ± 9.21 |
| Change from Core Baseline at Week 192 | 11.2 ± 9.21 | 11.0 ± 9.40 |
| Change from Core Baseline at Week 240 | 10.9 ± 9.58 | 11.4 ± 9.29 |
| Change from Core Baseline at Week 288 | 13.0 ± 10.71 | 13.1 ± 9.50 |
| Change from Core Baseline at Week 336 | 12.8 ± 10.12 | 12.0 ± 8.79 |
| Change from Core Baseline at Week 384 | 11.5 ± 9.97 | 11.7 ± 8.00 |
The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | 6.1 ± 9.67 | 7.1 ± 10.01 |
| Change from Core Baseline at Week 48 | 6.2 ± 10.52 | 6.8 ± 10.84 |
| Change from Core Baseline at Week 96 | 6.5 ± 10.54 | 6.7 ± 10.33 |
| Change from Core Baseline at Week 144 | 6.2 ± 10.72 | 6.6 ± 10.86 |
| Change from Core Baseline at Week 192 | 6.1 ± 11.47 | 7.5 ± 11.60 |
| Change from Core Baseline at Week 240 | 6.5 ± 11.11 | 7.7 ± 11.66 |
| Change from Core Baseline at Week 288 | 7.3 ± 11.49 | 8.2 ± 11.20 |
| Change from Core Baseline at Week 336 | 6.7 ± 10.49 | 6.6 ± 13.65 |
| Change from Core Baseline at Week 384 | 6.3 ± 11.23 | 8.0 ± 10.98 |
FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.
| score on a scale | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Change from Core Baseline at Extension Baseline | 10.7 ± 11.06 | 12.1 ± 10.71 |
| Change from Core Baseline at Week 48 | 11.6 ± 11.16 | 12.7 ± 11.62 |
| Change from Core Baseline at Week 96 | 12.0 ± 11.59 | 12.9 ± 10.97 |
| Change from Core Baseline at Week 144 | 12.3 ± 11.31 | 13.2 ± 11.92 |
| Change from Core Baseline at Week 192 | 11.7 ± 11.63 | 12.8 ± 11.96 |
| Change from Core Baseline at Week 240 | 11.5 ± 11.52 | 12.5 ± 11.74 |
| Change from Core Baseline at Week 288 | 13.4 ± 13.21 | 15.0 ± 12.03 |
| Change from Core Baseline at Week 336 | 13.2 ± 12.18 | 13.8 ± 12.29 |
| Change from Core Baseline at Week 384 | 12.6 ± 13.35 | 13.9 ± 10.76 |
Collected over From First dose to Week 437. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Filgotinib Darwin 1 | 8/497 (1.6%) | 84/497 (16.9%) | 386/497 (77.7%) |
| Filgotinib Darwin 2 | 8/242 (3.3%) | 48/242 (19.8%) | 189/242 (78.1%) |
| Event | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 7/497 | 3/242 |
| PneumoniaInfections and infestations | 7/497 | 3/242 |
| Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/497 | 3/242 |
| COVID-19 pneumoniaInfections and infestations | 6/497 | 2/242 |
| CholelithiasisHepatobiliary disorders | 5/497 | 1/242 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/497 | 2/242 |
| Femur fractureInjury, poisoning and procedural complications | 3/497 | 2/242 |
| Humerus fractureInjury, poisoning and procedural complications | 0/497 | 2/242 |
| Acute kidney injuryRenal and urinary disorders | 0/497 | 2/242 |
| Urinary tract infectionInfections and infestations | 0/497 | 2/242 |
| Event | Filgotinib Darwin 1 | Filgotinib Darwin 2 |
|---|---|---|
| Mycobacterium tuberculosis complex test positiveInvestigations | 58/497 | 40/242 |
| Upper respiratory tract infectionInfections and infestations | 57/497 | 37/242 |
| HypertensionVascular disorders | 75/497 | 27/242 |
| Urinary tract infectionInfections and infestations | 72/497 | 30/242 |
| NasopharyngitisInfections and infestations | 70/497 | 24/242 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 39/497 | 30/242 |
| BronchitisInfections and infestations | 59/497 | 19/242 |
| HeadacheNervous system disorders | 34/497 | 26/242 |
| Blood cholesterol increasedInvestigations | 13/497 | 23/242 |
| LymphopeniaBlood and lymphatic system disorders | 45/497 | 23/242 |
The Safety Analysis Set included all participants who enrolled in the extension study and received at least one dose of study drug. As prespecified in the protocol, data was collected and analyzed based on their originating parent study I.e. DARWIN 1 and DARWIN 2.
| Age, Continuous(years) | Filgotinib Darwin 1 | Filgotinib Darwin 2 | Total |
|---|---|---|---|
| Mean | 53 ± 11.7 | 52 ± 12.2 | 53 ± 11.9 |
| Sex: Female, Male(Participants) | Filgotinib Darwin 1 | Filgotinib Darwin 2 | Total |
|---|---|---|---|
| Female | 405 | 198 | 603 |
| Male | 92 | 44 | 136 |
| Ethnicity (NIH/OMB)(Participants) | Filgotinib Darwin 1 | Filgotinib Darwin 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 208 | 85 | 293 |
| Not Hispanic or Latino | 289 | 157 | 446 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Filgotinib Darwin 1 | Filgotinib Darwin 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 3 | 3 | 6 |
| White | 374 | 181 | 555 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 119 | 56 | 175 |
Showing the first 100 of 111 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for clinical trials that support an approved indication in the EU and the US for which Galapagos is the Marketing Authorisation / New Drug Application Holder, with a marketing authorisation date on or after January 1, 2021 and for which the summary results have been published on ClinicalTrials.gov (CT.gov) and/or the EU Clinical Trials Register (EU CTR). For clinical trials of newly approved compounds or indications the IPD can be requested at earliest 6 months after the EMA and FDA approval. The study last patient last visit (LPLV) must have occurred at least 18 months prior to the request.
Ran from Feb 2014 to primary completion in Jan 2023, 106 months.
Results were first posted in Jun 2024, 1 year 4 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 106 months is above that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634